This report was first published by Endpoints News. To see the original version, click here
In what is shaping up to be one of the most active years for biopharma M&A on record, a different-looking set of buyers is going shopping.
Mid-cap American drugmakers, family-owned pharma groups, foundation-governed European players, Japan-based conglomerates, the AI giant Anthropic and other non-traditional acquirers are taking part in the biotech M&A bonanza.
您已阅读8%（452字），剩余92%（5040字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。